Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTT-4: baricitinib + remdesivir versus dexamethasone + remdesivir in hospitalized adults with COVID-19
jRCT2031200252Completed
- Sponsor
- Ministry of Health, Labour and Welfare
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Baricitinib + remdesivir with Dexamethasone + remdesivir (2 arms). Primary endpoints: Mechanical ventilation-free survival by Day 29 and Clinical status on 8-point ordinal scale at Day 15. Started Jan 2021; status: completed.
02
Drugs
baricitinibdexamethasoneremdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031200252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200252.